284 / 400
MONDAY
TUESDAY
WEDNESDAY
THURSDAY
POSTER SESSIONS
276
005
Sustained remission and symptomatic stability
among patients with schizophrenia receiving
aripiprazole once-monthly in a 52-week, open-label,
maintenance study
Timothy Peters-Strickland, USA
Na Jin, Pedro Such, Phyllis M. Salzman
006
Priapism following augmentation treatment
with quetiapine: a case report
Razan Alkhoury, Germany
Marius Bolten, Gisbert Eikmeier
007
A randomized controlled trial of pharmacist
intervention on cognitive outcomes in patients with
schizophrenia
Thanarat Suansanae, Thailand
Thanompong Sathienluckana, Weerapon
Unaharassamee, Oraporn Suanchang, Chuthamanee
Suthisisang
008
Evaluation of clozapine total clearance from
therapeutic drug monitoring data
Melissa Ballestrin, Italy
Ekkehard Haen
009
Outpatient's clozapine initiation at treatment
resistant schizophrenic patients in a rural Greek
hospital: protocol – results
Argitis Petros, Greece
Konstantina Mpaklori, Sofia Skopelitou, Paraskevi
Platari, Andreas Karampas, Anthi Plevritaki, Lampros
Sakkas, Maria Poulou
010
Eosinophilia secondary to clozapine:
about a case
Mónica Rodríguez Merino, Spain
Jorge Schoendorff Ortega, Juan José Arechederra
Aranzadi, Mariano Hernández Herreros, Ana Judith
Mesa Suárez, Luis Enrique Vidal Palmer, María Inéz
López-Ibor
011
Treatment with haloperidol in the light of
current efficacy and safety knowledge
Christine Greiner, Germany
Annette Viktoria Hinze, Martin Huber
012
Lumateperone (ITI-007): a unique investiga-
tional agent with broad therapeutic potential across
neuropsychiatric disorders
Cedric O'Gorman, USA
Kimberly Vanover, Christoph U. Correll, Steve Glass,
Sharon Mates, Jelena Saillard, Michal Weingart, Robert
Davis
013
A retrospective analysis of antipsychotic
combination vs. monotherapy treatment in a long
term psychiatric facility
Jose Rey, USA
Yesenia Sanin, Stepan Uhlyar
014
Drug-induced parkinsonism among patients
receiving anti-psychotic medications in a Nigerian
hospital
Fatima Olaiya, Nigeria
Champion Seun-Fadipe, Kolawole Mosaku
015
Medication discrepancies among demented
persons in home care settings with or without
treatment by a neurologist
Leonhard Schütz, Germany
Nils Lahmann, Ralf Suhr, Xavier Boronat-Garrido,
Fabian Alexander Moser
P-36
Poster Session
13:30– 15:00
|
Hall Budapest
TOPIC 18:
Pharmacotherapy
Pharmacotherapy III
Chair:
Christoph Hiemke, Germany
001
Safety of DPP-4 inhibitor on anxiety and
depression among type 2 diabetes: a systematic
review and network meta-analysis
Weiwei Wang, People's Republic of China
Feng Sun, Shanshan Wu, Siyan Zhan
002
Protocol for the evaluation of the physiochem-
ical properties of 3 generic psychotropic essential
medications in South-South Nigeria
Frances Adiukwu, Nigeria
Chidozie Chukwujekwu, Ibipiriene Wakama, Princewill
Stanley
003
A meta-analysis of the efficacy of silexan in
subthreshold anxiety
Stephan Klement, Germany
Hans-Peter Volz, Siegfried Kasper
004
Comparison of anxiolytic effects of the homeo-
pathic complex vita-C 15 in compared with aconi-
tum napellus in the acutely stressed C57BL6 mice
Charis Liew, Malaysia
005
In silico and in vitro study of bromdihydro-
chlorphenylbenzodiazepines – Russian original
benzodiazepine-metabolical pathways
Dmitriy Ivashchenko, Russia
Andrey Poloznikov, D. A. Filimonov, Sergey Nikulin,
A. V. Rudik, Alexander Dmitriev, Lyudmila Savchenko,
Eugeniy Bryun
006
Memantine augmentation improves symptoms
in patients with treatment-refractory obsessive-
compulsive disorder: a randomized controlled trial
Setareh Razoughi, Iran
Mehdi Sayyah, Leila Kouti, Kaveh Eslami
007
Efficacy of intravenous ketamine for treatment
of acute post traumatic stress disorder
Achyut Trivedi, India
Ashok Singhal